Cancers, Vol. 14, Pages 573: High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC
Conclusion: The evidence regarding curative re-irradiation for centrally recurrent NSCLC is primarily based on scarce retrospective data, which are characterized by a high degree of heterogeneity. The OS in this clinically challenging situation is expected to be around 1.5 years after re-treatment. Patients with a good performance score, younger age, small tumors, and a longer interval to recurrence potentially benefit most from re-irradiation. In this context, prospective trials are warranted to achieve substantial advances in the field.
Source: Cancers - Category: Cancer & Oncology Authors: Brane Grambozov Markus Stana Bernhard Kaiser Josef Karner Sabine Gerum Elvis Ruznic Barbara Zellinger Raphaela Moosbrugger Michael Studnicka Gerd Fastner Felix Sedlmayer Franz Zehentmayr Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Palliative | Study | Toxicology